Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies.

ABSTRACT:

Aims

To evaluate the immunogenicity and safety of a seasonal influenza vaccine in a cohort of multiple sclerosis (MS) patients receiving different immunomodulating/immunosuppressive therapies and assess predictors of immune response.

Methods

A prospective, multicenter, non-randomized observational study including 108 patients receiving a trivalent seasonal influenza vaccination was conducted. Influenza-specific antibody titers (H1N1, H3N2, and influenza B) were measured to evaluate rates of seroprotection and seroconversion/significant titer increase. Univariable and multivariable analyses were performed to identify prognostic factors of vaccination outcomes.

Results

Regarding the whole cohort, seroprotection rates >70% were achieved for each influenza strain. Interfe

SUBMITTER: Metze C 

PROVIDER: S-EPMC6488907 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature